Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Completed · Phase 2 · NCT04409509
Conditions: Coronavirus Disease 2019 (COVID-19)
At a glance
- Research payments reported, 2025
- $6,281
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 124
About the trial
- Sponsor
- CSL Behring
- Tested
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (biological), Placebo (drug)
- Dates
- Started 2020-07-01; completion 2021-01-12
- Results posted
- Yes
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
From ClinicalTrials.gov, last updated 2022-01-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $6,281 in research payments for this study in 2025 (2 payments).
Products named: Andembry
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Carla Lamb, M.D. Pulmonology · Burlington, MA
- Anthony J. Comerota, M.D. Vascular Surgery · Falls Church, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Inova Fairfax Hospital, VA $3,732
- Lahey Clinic, Inc. $2,550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.